Could a shot of your own blood ease menopause symptoms?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least one clinical complaint of VVA. * Dryness * Burning * Itching * Discomfort (soreness, irritation) * Dyspareunia (sexual impaired function) * With or without urinary problems (incontinence, urgency, dysuria). Must report a contra-indication with the standard local hormonal treatment. * Allergy * Burden side effects * Non-improvement with standard treatment * Hormonal cancer survivors must be in remission for two years after the last oncologic treatment. * Thrombotic disease patients must have the disease controlled and have passed 2 years after the thrombotic event. Must have a cervicovaginal cytology confirming the atrophy, having ≤ 5% of superficial cells on vaginal smear. Moreover, a normal morphologic cytology besides the inflammatory or atrophy change is mandatory. Must have a vaginal pH above 5 at baseline. Must have a normal mammography (American College of Radiology BI-RADS 1 or 2) within 12 months of study starts (Day 1), and normal breast examination. Willing to participate in the study and sign an informed consent. Exclusion Criteria: * Life expectancy \< 6 months due to concomitant illnesses. * Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study. * Active infectious disease. Patients known to have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM \> IgG) and/or syphilis will have an expert consultation as to patient eligibility based on the patient's infectious status. * Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results. * Patients on chronic immunosuppressive transplant therapy. * Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate. * Used oral, transdermal, vaginal, intrauterine, implants/injectables drugs that contained either oestrogens, progestins, androgens, or selective oestrogen receptor modulators (SERMs) before the study (a washout period of 4 weeks is required). Use of prescription and non-prescription medications and remedies known to alleviate VVA, discomfort including vaginal lubricants and moisturizers, are allowed during the study. * Any allergic reaction to local anaesthetics. * Unwilling and/or not able to give written informed consent.